<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057117</url>
  </required_header>
  <id_info>
    <org_study_id>MWT-BTXA</org_study_id>
    <secondary_id>2021-000877-10</secondary_id>
    <secondary_id>H-21013548</secondary_id>
    <nct_id>NCT05057117</nct_id>
  </id_info>
  <brief_title>Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis</brief_title>
  <official_title>Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis: a Randomized Intra-individual Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merete Haedersdal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims is to assess and compare treatment effect of microwave thermolysis and&#xD;
      botulinum toxin A for axillary hyperhidrosis with focus on longevity. The investigators also&#xD;
      aim to assess patient satisfaction and adverse reactions in relation to treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A single-center, prospective, randomized, intra-individual, clinicial trial comparing longterm efficacy of two treatments for axillary hyperhidrosis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective change in axillary sweat</measure>
    <time_frame>Baseline - 6 months</time_frame>
    <description>Unilateral sweat change from baseline to 6 months follow-up assessed by Hyperhidrosis Disease Severity Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective change in axillary sweat</measure>
    <time_frame>Baseline - 6 months</time_frame>
    <description>Unilateral sweat change from baseline to 6 months follow-up assessed by gravimetric test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>Baseline - 6 months - 12 months</time_frame>
    <description>Unilateral patient satisfaction 6 and 12 months after treatments assessed on a 3-point Likert Scale (unsatisfied - neutral - satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>Baseline - 12 months</time_frame>
    <description>Unilateral evaluation of adverse reactions after treatments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperhidrosis Primary Focal Axilla</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One treatment with standard dosage (50-100 units) of botulinum toxin A in one axilla</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microwave thermolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One standard treatment (energy level 5) with microwave thermolysis in one axilla</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microwave thermolysis</intervention_name>
    <description>Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization</description>
    <arm_group_label>Microwave thermolysis</arm_group_label>
    <other_name>miraDry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <description>Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization</description>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has provided written informed consent&#xD;
&#xD;
          2. Subject is 18 years of age or older&#xD;
&#xD;
          3. A unilateral HDSS score of 3 or 4 for each axilla&#xD;
&#xD;
          4. A gravimetric measurement of at least 50 mg/5 min for women and 100 mg/5 min for men&#xD;
             in at least one axilla. The contralateral axilla should not be below 40 mg (women) and&#xD;
             80 mg (men).&#xD;
&#xD;
          5. Women of childbearing potential must be confirmed not pregnant by a negative u-HCG&#xD;
             prior to study treatment and must use a safe contraceptive method at baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with generalized hyperhidrosis&#xD;
&#xD;
          2. Medical condition or medications that may alter perspiration (e.g. metabolic,&#xD;
             immunological or infectious diseases, antidepressants, opioids, adrenergic/cholinergic&#xD;
             drugs)&#xD;
&#xD;
          3. Daily use of systemic or topical antibiotics and/or steroids in axillae at the time of&#xD;
             inclusion&#xD;
&#xD;
          4. Topical treatments for axillary hyperhidrosis (anti-perspirants are allowed except for&#xD;
             visit days)&#xD;
&#xD;
          5. Abnormal skin (e.g. rash, infection, dermatitis) in the axilla at the time of&#xD;
             inclusion&#xD;
&#xD;
          6. Breast tissue in the axillae&#xD;
&#xD;
          7. Treatment with Isotretinoin within the past 6 months&#xD;
&#xD;
          8. Axillary laser or IPL treatment within the past 6 months&#xD;
&#xD;
          9. Botulinum toxin-injections in the axillae within the past 12 months prior to baseline&#xD;
&#xD;
         10. Known allergies to botulinum toxin, iodine, lidocaine or adrenaline&#xD;
&#xD;
         11. Prior axillary surgery&#xD;
&#xD;
         12. Limited motion in the shoulder joint or neurologic deficit in upper limb&#xD;
&#xD;
         13. History of diseases resulting in muscle weakness (ALS, Lou Gehrig's), dysphagia&#xD;
             (Myasthenia Gravis or Lambert Eaton Syndrome) or respiratory compromise&#xD;
&#xD;
         14. Axillary lymph node enlargement or -removal or lymphedema in either upper limb&#xD;
&#xD;
         15. History of hidradenitis suppurativa or history of reoccurring infections/abscesses&#xD;
&#xD;
         16. History of breast cancer&#xD;
&#xD;
         17. Electronic device implant&#xD;
&#xD;
         18. If female; lactating, pregnant or planning on becoming pregnant during the study&#xD;
&#xD;
         19. Non-eligibility at the discretion of the investigator (e.g. non-compliance,&#xD;
             unavailability or other reasons the subject is not believed to be able to comply with&#xD;
             the clinical trial protocol)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merete Haedersdal, MD PhD DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriela Grove, MD</last_name>
    <phone>+4538636173</phone>
    <email>ggro0013@regionh.dk</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Merete Haedersdal</investigator_full_name>
    <investigator_title>Consultant in Dermatology, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Axillary hyperhidrosis</keyword>
  <keyword>Microwave thermolysis</keyword>
  <keyword>Botulinum toxin A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

